{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:47:22Z","timestamp":1772120842717,"version":"3.50.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejog.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.ejogrb.2013.07.010","type":"journal-article","created":{"date-parts":[[2013,8,8]],"date-time":"2013-08-08T11:15:58Z","timestamp":1375960558000},"page":"439-443","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Prevention of ovarian hyperstimulation syndrome in GnRH agonist IVF cycles in moderate risk patients: randomized study comparing hydroxyethyl starch versus cabergoline and hydroxyethyl starch"],"prefix":"10.1016","volume":"170","author":[{"given":"Roberto","family":"Matorras","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maider","family":"Andr\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosario","family":"Mendoza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bego\u00f1a","family":"Prieto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose Ignacio","family":"Pijoan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonia","family":"Exp\u00f3sito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejogrb.2013.07.010_bib0005","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1093\/humrep\/deh816","article-title":"Request for information on unreported cases of severe ovarian hyperstimulations syndrome (OHSS)","volume":"20","author":"Delvinge","year":"2005","journal-title":"Hum Reprod"},{"key":"10.1016\/j.ejogrb.2013.07.010_bib0010","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s10815-010-9387-6","article-title":"Ovarian hyperstimulation syndrome: pathophysiology and prevention","volume":"27","author":"Nastri","year":"2010","journal-title":"J Assist Reprod Genet"},{"key":"10.1016\/j.ejogrb.2013.07.010_bib0015","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1093\/humupd\/dmr008","article-title":"GnRH agonist for triggering of final oocyte maturation: time for a change of practice","volume":"17","author":"Humaidan","year":"2011","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.ejogrb.2013.07.010_bib0020","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1093\/oxfordjournals.humrep.a138185","article-title":"The use of intravenous albumin in patients at high risk of severe ovarian hyperstimulation syndrome","volume":"8","author":"Asch","year":"1993","journal-title":"Hum Reprod"},{"key":"10.1016\/j.ejogrb.2013.07.010_bib0025","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/HUMREP\/10.6.1373","article-title":"Decreased incidence of ovarian hyperstimulation syndrome in high risk in-vitro fertilization patients receiving intravenous albumin: a prospective study","volume":"10","author":"Shalev","year":"1995","journal-title":"Hum Reprod"},{"key":"10.1016\/j.ejogrb.2013.07.010_bib0030","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0301-2115(95)02603-7","article-title":"Intravenous albumin prevents moderate-severe ovarian hyperstimulation in in-vitro fertilization patients: a prospective, randomized and controlled study","volume":"70","author":"Isik","year":"1996","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.ejogrb.2013.07.010_bib0035","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1093\/humrep\/15.5.1037","article-title":"Value of serum and follicular fluid cytokine profile in the prediction of moderate to severe ovarian hyperstimulation syndrome","volume":"15","author":"Chen","year":"2000","journal-title":"Hum Reprod"},{"key":"10.1016\/j.ejogrb.2013.07.010_bib0040","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0301-2115(01)00364-5","article-title":"The detrimental role of colloidal volume substitutes in severe ovarian hyperstimulation syndrome: a case report","volume":"99","author":"Kissler","year":"2001","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.ejogrb.2013.07.010_bib0045","first-page":"CD001302","article-title":"Intra-venous fluids for the prevention of severe ovarian hyperstimulation syndrome","volume":"16","author":"Youssef","year":"2011","journal-title":"CDS Rev"},{"key":"10.1016\/j.ejogrb.2013.07.010_bib0050","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/humupd\/8.6.559","article-title":"Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review","volume":"8","author":"Delvigne","year":"2002","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.ejogrb.2013.07.010_bib0055","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1093\/humupd\/dmq006","article-title":"Can dopamine agonists reduce the incidence and severity of OHSS in IVF\/ICSI treatment cycles? A systematic review and meta-analysis","volume":"16","author":"Youssef","year":"2010","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.ejogrb.2013.07.010_bib0060","first-page":"CD008605","article-title":"Cabergoline for preventing ovarian hyperstimulation syndrome","volume":"2","author":"Tang","year":"2012","journal-title":"CDS Rev"},{"key":"10.1016\/j.ejogrb.2013.07.010_bib0065","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1093\/humrep\/dem315","article-title":"Implantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study","volume":"12","author":"Alvarez","year":"2007","journal-title":"Hum Reprod"},{"key":"10.1016\/j.ejogrb.2013.07.010_bib0070","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1210\/jc.2007-0409","article-title":"Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction","volume":"92","author":"Alvarez","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ejogrb.2013.07.010_bib0075","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1210\/en.2002-220204","article-title":"Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats and this effect is prevented by receptor blockade","volume":"143","author":"Gomez","year":"2002","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejogrb.2013.07.010_bib0080","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1093\/humrep\/17.7.1762","article-title":"Ultrasound-guided embryo transfer improves pregnancy rates and increases the frequency of easy transfers","volume":"17","author":"Matorras","year":"2002","journal-title":"Hum Reprod"},{"key":"10.1016\/j.ejogrb.2013.07.010_bib0085","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1093\/humrep\/deh366","article-title":"Influence of the time interval between embryo catheter loading and discharging on the success of IVF","volume":"19","author":"Matorras","year":"2004","journal-title":"Hum Reprod"},{"key":"10.1016\/j.ejogrb.2013.07.010_bib0090","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.rbmo.2009.09.016","article-title":"Mid-follicular LH supplementation in women aged 35\u201339 years undergoing ICSI cycles: a randomized controlled study","volume":"19","author":"Matorras","year":"2009","journal-title":"Reprod Biomed Online"},{"key":"10.1016\/j.ejogrb.2013.07.010_bib0095","doi-asserted-by":"crossref","first-page":"c332","DOI":"10.1136\/bmj.c332","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Schulz","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.ejogrb.2013.07.010_bib0100","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1097\/00006254-198906000-00004","article-title":"Ovarian hyperstimulation syndrome: an update review","volume":"44","author":"Golan","year":"1989","journal-title":"Obstet Gynecol Surv"},{"key":"10.1016\/j.ejogrb.2013.07.010_bib0105","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1093\/oxfordjournals.humrep.a138598","article-title":"Early and late presentation of the ovarian hyperstimulation syndrome: two distinct entities with different risk factors","volume":"9","author":"Lyons","year":"1994","journal-title":"Hum Reprod"},{"key":"10.1016\/j.ejogrb.2013.07.010_bib0110","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1093\/oxfordjournals.humrep.a138260","article-title":"The ovarian hyperstimulation syndrome in in-vitro fertilization: a Belgian multicentric study. I. Clinical and biological features","volume":"8","author":"Delvigne","year":"1993","journal-title":"Hum Reprod"},{"key":"10.1016\/j.ejogrb.2013.07.010_bib0115","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1093\/oxfordjournals.humrep.a138261","article-title":"The ovarian hyperstimulation syndrome in in-vitro fertilization: a Belgian multicentric study. II. Multiple discriminant analysis for risk prediction","volume":"9","author":"Delvigne","year":"1993","journal-title":"Hum Reprod"},{"key":"10.1016\/j.ejogrb.2013.07.010_bib0120","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1196\/annals.1365.021","article-title":"Prevention and management of ovarian hyperstimulation syndrome","volume":"1092","author":"Vlahos","year":"2006","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ejogrb.2013.07.010_bib0125","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1093\/humrep\/dei475","article-title":"Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial","volume":"21","author":"Babayof","year":"2006","journal-title":"Hum Reprod"},{"key":"10.1016\/j.ejogrb.2013.07.010_bib0130","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.fertnstert.2007.02.002","article-title":"The use of gonadotrophin-releasing hormone (9GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high risk patients undergoing in vitro fertilization syndrome: a prospective randomized controlled study","volume":"89","author":"Engmann","year":"2008","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ejogrb.2013.07.010_bib0135","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/0002-9378(88)90523-6","article-title":"Risk factors and prognostic variables in the ovarian hyperstimulation syndrome","volume":"159","author":"Navot","year":"1988","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ejogrb.2013.07.010_bib0140","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1093\/oxfordjournals.humrep.a136044","article-title":"Predictive value of serum oestradiol concentrations and oocyte number in severe ovarian hyperstimulation syndrome","volume":"4","author":"Morris","year":"1995","journal-title":"Hum Reprod"},{"key":"10.1016\/j.ejogrb.2013.07.010_bib0145","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S0015-0282(00)00492-1","article-title":"Distinction between early and late ovarian hyperstimulation syndrome","volume":"73","author":"Mathur","year":"2000","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ejogrb.2013.07.010_bib0150","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1093\/humrep\/12.12.2599","article-title":"Reduced incidence of ovarian hyperstimulation syndrome by prophylactic infusion of hydroxyaethyl starch solution in an in-vitro fertilization programme","volume":"12","author":"Graf","year":"1997","journal-title":"Hum Reprod"},{"key":"10.1016\/j.ejogrb.2013.07.010_bib0155","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.rbmo.2013.03.002","article-title":"Clinical outcome according to timing of cabergoline initiation for prevention of OHSS: a randomized controlled trial","volume":"26","author":"Seow","year":"2013","journal-title":"Reprod Biomed Online"},{"key":"10.1016\/j.ejogrb.2013.07.010_bib0160","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0301-2115(00)00452-8","article-title":"Intravenous albumin versus hydroxyethyl starch for the prevention of ovarian hyperstimulation in an in-vitro fertilization programme: a prospective randomized placebo controlled study","volume":"96","author":"Gokmen","year":"2001","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.ejogrb.2013.07.010_bib0165","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1093\/humrep\/13.9.2421","article-title":"Prophylactic intravenous hydroxyethyl starch solution prevents moderate-severe ovarian hyperstimulation in in-vitro fertilization patients: a prospective, randomized, double-blind and placebo-controlled study","volume":"13","author":"Konig","year":"1998","journal-title":"Hum Reprod"},{"key":"10.1016\/j.ejogrb.2013.07.010_bib0170","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S1472-6483(10)60401-4","article-title":"Cabergoline reduces the early onset of ovarian hyperstimulation syndrome: a prospective randomized study","volume":"17","author":"Carizza","year":"2008","journal-title":"Reprod Biomed Online"},{"key":"10.1016\/j.ejogrb.2013.07.010_bib0175","series-title":"Abstracts of the 25th annual meeting of ESHRE 2009","article-title":"Role of cabergoline in preventing ovarian hyperstimlation syndrome in high risk intracytoplasmic sperm injection (ICSI) patients and effect on outcome","author":"Shaltout","year":"2009"},{"key":"10.1016\/j.ejogrb.2013.07.010_bib0180","series-title":"Abstracts of the 25th annual meeting of ESHRE 2009","article-title":"Can cabergoline prevent ovarian hyperstimulation syndrome in PCO patients undergoing gonadotropin stimulation? Comparative study with prednisolone","author":"Salah Edeen","year":"2009"},{"key":"10.1016\/j.ejogrb.2013.07.010_bib0185","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMoa054830","article-title":"Valvular heart disease and the use of dopamine agonists for Parkinson's disease","volume":"356","author":"Zanettini","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejogrb.2013.07.010_bib0190","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ejogrb.2012.08.008","article-title":"Can dopamine agonist at a low dose reduce ovarian hyperstimulation syndrome in women at risk undergoing ICSI treatment cycles: a randomized controlled study","volume":"165","author":"Shaltout","year":"2012","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.ejogrb.2013.07.010_bib0195","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa062222","article-title":"Dopamine agonists and the risk of cardiac-valve regurgitation","volume":"356","author":"Schade","year":"2007","journal-title":"N Engl J Med"}],"container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211513003175?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211513003175?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T05:29:13Z","timestamp":1759555753000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301211513003175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S0301211513003175"],"URL":"https:\/\/doi.org\/10.1016\/j.ejogrb.2013.07.010","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718072126.793488021","asserted-by":"object"}]},"ISSN":["0301-2115"],"issn-type":[{"value":"0301-2115","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevention of ovarian hyperstimulation syndrome in GnRH agonist IVF cycles in moderate risk patients: randomized study comparing hydroxyethyl starch versus cabergoline and hydroxyethyl starch","name":"articletitle","label":"Article Title"},{"value":"European Journal of Obstetrics & Gynecology and Reproductive Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejogrb.2013.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}